Both are long synthetic peptides studied in metabolic signalling, and the headline difference is how many receptors each engages. That difference is real, but the one that affects you at the point of buying is which of the two can be checked against a public record.
The receptor count
Tirzepatide engages two receptors, GIP and GLP-1. Retatrutide engages those two and the glucagon receptor as well.
GIP and GLP-1 are the two incretin hormones, released from the gut and acting on their own receptors. (Reference: Baggio & Drucker, 2007) Glucagon belongs to the same receptor family but is a different signal, released from the pancreas. So the step from two to three adds a receptor whose natural ligand comes from somewhere else, which is a different kind of addition. Our notes on incretins and GLP-1 versus GIP cover the family.
"Agonist" at all three does not mean equal at all three. A molecule can be a full agonist at one receptor and partial at another, and can also favour one downstream pathway over another at the same receptor, which has been described for tirzepatide at GLP-1. (Reference: Willard et al., 2020) A receptor count is a label, not a profile.
Why the glucagon receptor is the interesting addition
GIP, GLP-1 and glucagon receptors all belong to the same structural class, the secretin-like family of G protein-coupled receptors, which is why one molecule can plausibly be designed to fit all three. (Reference: Mayo et al., 2003) Family resemblance is what makes a triple agonist chemically conceivable instead of fanciful.
It also makes selectivity harder to assert. Receptors that resemble each other are receptors a molecule can bind to by accident, so a claim about which three a compound engages is a claim about measured binding, not about intent. That is a question for the published pharmacology and not for a certificate of analysis, and it is worth keeping the two kinds of document apart: a certificate says what is in the vial, never what it does.
Identity on paper
Tirzepatide is C225H348N48O68, 4813.45 g/mol, CAS 2023788-19-2, with a PubChem record.
Retatrutide is where the asymmetry shows. It has no CAS number in our catalogue and no PubChem entry; the identifier that resolves is its ChEMBL record. That is what a newer compound looks like in the reference databases, and no reflection on the compound: an identifier is assigned once a substance has been indexed, and indexing follows publication.
The consequence is practical. For tirzepatide you can take the CAS number, run the check digit, look it up, and read back which substance it returns. For retatrutide that route does not exist, so the identity evidence has to come from the certificate itself and not from a public register.
What that does to verification
With a compound that has a public record, a certificate has a second opinion available: the measured mass can be compared against a mass calculated from a published formula, and you can check the two independently.
Without one, the mass spectrum on the certificate is the identity evidence, and there is nothing external to cross it against. That raises the weight carried by the rest of the document: whether a method sits next to each number, whether there is a date, whether a laboratory is named. Our supplier checklist walks through it, and the interactive version is the same seven checks.
This is the part worth being plain about. A compound being newer than its paperwork is normal. A supplier treating that as a reason to show you less is not.
What a certificate should show for either
The same fields, for the same reasons. Purity from RP-HPLC with its conditions written out, because the column and gradient change the number. Identity from mass spectrometry, with observed and theoretical mass both shown. Net peptide content separate from chromatographic purity, because a batch can be 99 percent pure by area and well below that by mass.
Both are long peptides, which matters for the purity figure: the longer the synthesis, the more chances for a coupling step not to finish, and deletion sequences differ from the target by a single residue and sit close to the main peak.
Mass, and why the figures look so close
Tirzepatide is 4813.45 g/mol and retatrutide 4894.58, a difference of about 81 units on molecules of nearly five thousand. On that scale an identity check cannot rest on a rounded number: two long peptides can differ by one residue and still look alike to one decimal place.
This is where the distinction between average and monoisotopic mass stops being pedantry. A mass spectrometer reports the monoisotopic value for the first peak of the isotope cluster, while a catalogue quotes the average, and on molecules this large the two differ by several units. Comparing one against the other is a reliable way to conclude that a correct batch is wrong. Our molecular weight calculator returns both, and our note on average versus monoisotopic mass explains the gap.
Storage is the same problem for both
Nothing in the receptor difference changes how either behaves in a vial. Both arrive lyophilised, both are hygroscopic, and both degrade by routes that proceed with time and temperature. A certificate is dated because a result belongs to a moment, and what happens between that date and your bench is a matter of storage, not of paperwork. Our note on storage covers the reasoning.
What this comparison is not
It is not a ranking, and it says nothing about what either compound does in an organism. Both are sold here for laboratory research, and the only comparison that belongs on a storefront is between what can be documented about each.
Research use only
All products sold by Codex Research are strictly for laboratory research and development. They are not for human or animal consumption and are not intended to diagnose, treat, cure, or prevent any disease.
These compounds in the catalog
Frequently asked questions
What is the difference between tirzepatide and retatrutide?
Tirzepatide engages two receptors, GIP and GLP-1. Retatrutide engages those two plus the glucagon receptor. Glucagon belongs to the same receptor family but is a different signal, released from the pancreas and not the gut.
Does engaging three receptors mean three times the activity?
No. A molecule can be a full agonist at one receptor and partial at another, and can favour one downstream pathway over another at the same receptor. A receptor count is a label, not a profile.
Why does retatrutide have no CAS number?
An identifier is assigned once a substance has been indexed in the chemical literature, and indexing follows publication. A newer compound may not have one yet, and that is not a defect.
Is retatrutide harder to verify than tirzepatide?
The public cross-check is harder. Tirzepatide has a CAS number and a PubChem record, so a measured mass can be compared against a published formula independently. For retatrutide the identity evidence has to come from the certificate itself.
What should the certificate show for either compound?
Purity by RP-HPLC with its conditions, identity by mass spectrometry with observed and theoretical mass both shown, net peptide content stated separately from chromatographic purity, a date, and a named laboratory.
Why does peptide length matter for purity here?
Both are long peptides. The longer the synthesis, the more opportunities for a coupling step not to finish, and the resulting deletion sequences differ from the target by a single residue and elute close to the main peak.
References
- Baggio, L.L., & Drucker, D.J. (2007). Biology of incretins: GLP-1 and GIP. Gastroenterology, 132(6), 2131-2157.
- Willard, F.S., et al. (2020). Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight, 5(17), e140532.
- Mayo, K.E., et al. (2003). International Union of Pharmacology. XXXV. The glucagon receptor family. Pharmacological Reviews, 55(1), 167-194.
- Tirzepatide compound summary (CID 156588324). PubChem, National Library of Medicine.
- Retatrutide (LY3437943). ChEMBL, European Bioinformatics Institute (CHEMBL5095485).